Open Access68Ga-DOTATATE positron emission tomography/computed tomography to detect the recurrence of phosphaturic mesenhcymal tumor-induced osteomalacia
Author(s) -
Manav Bhalla,
Kennedy M Wirtz,
Eric Fair,
Daniel Bucklan
Publication year - 2020
Publication title -
world journal of nuclear medicine
Language(s) - English
Resource type - Journals
eISSN - 1607-3312
pISSN - 1450-1147
DOI - 10.4103/wjnm.wjnm_92_18
Subject(s) - medicine , positron emission tomography , neuroendocrine tumors , somatostatin receptor , radiology , osteomalacia , positron emission tomography computed tomography , paraganglioma , octreotide , nuclear medicine , lesion , pet ct , pathology , somatostatin , osteoporosis
68Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) has shown superiority over111Indium-octreotide scanning for the detection of phosphaturic mesenchymal tumors (PMTs). We report a case of tumor-induced osteomalacia resulting from PMT which, although initially clinically suspected, was not localized on octreotide scintigraphy performed several years prior. Subsequent surgical excision of a presumed benign osseous lesion a few years later revealed the diagnosis on pathology. Imaging assessment using 68Ga-DOTATATE PET/CT following recent clinical suspicion for recurrence revealed an intense tracer-avid lesion at the primary tumor site. DOTATATE imaging plays an important role in localizing tumors with high somatostatin receptor expression, such as neuroendocrine tumors (pheochromocytoma, paraganglioma, and neuroblastoma), meningioma, and mesenchymal tumors, causing oncogenic osteomalacia.